High-Dose Cryopreserved Bone Marrow from Deceased Donors May Reduce Relapse in HLA-Mismatched Allogeneic Transplantation: Day 180 Post-Transplant HOPE Update

Key Points

• High-dose cryopreserved bone marrow significantly reduces relapse rates in HLA-mismatched allogeneic transplantation.
• At Day 180 post-transplant, early indicators show improved patient outcomes with this approach.
• Observational analysis of patients receiving cryopreserved bone marrow demonstrates its promising effects on relapse.
• These findings highlight the potential benefits of enhanced donor selection processes for improved transplant success.